Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $165.00 short put and a strike $155.00 long put offers a potential 19.33% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $165.00 by expiration. The full premium credit of $1.62 would be kept by the premium seller. The risk of $8.38 would be incurred if the stock dropped below the $155.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 43.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Thu, 16 Nov 2017 13:00:00 +0000
DUBLIN, Nov. 16, 2017 /PRNewswire/ — Allergan plc (AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and Development Officer, and Armin Szegedi, Allergan's Vice President of Clinical Development/CNS, will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston, Massachusetts. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at www.allergan.com/investors. Allergan plc (AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Inside Novartis’s Ophthalmology Drugs Now
Wed, 15 Nov 2017 12:32:32 +0000
In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
An Undervalued, Wide-Moat Name in Healthcare
Wed, 15 Nov 2017 11:33:09 +0000
We think generic competition on Restasis is manageable and that Allergan has an innovative pipeline and strong aesthetics business.
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
Tue, 14 Nov 2017 21:16:09 +0000
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today
Tue, 14 Nov 2017 19:54:00 +0000
The company's making inroads with its first commercial-stage drug, but expenses could present big headwinds.
Also on Market Tamer…
Follow Us on Facebook